Chemotherapy in advanced bladder cancer: Current status and future

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Ismaili, Nabil ^a   Amzerin, Mounia ^b   Flechon, Aude ^c  

^a Centre Régional d'Oncologie   (Morocco)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOVITINIB; DOXORUBICIN; EPIRUBICIN; ERIBULIN; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; LAPATINIB; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; SORAFENIB; SUNITINIB; TRASTUZUMAB; TRIMETREXATE; UNINDEXED DRUG; VINBLASTINE; VINFLUNINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; BLADDER CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; DEHYDRATION; DIARRHEA; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GLOMERULUS FILTRATION RATE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPONATREMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG TOXICITY; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PROGNOSIS; RASH; REVIEW; SENSORY NEUROPATHY; SEPSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; VOMITING; BLADDER TUMOR;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 80052582598     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-35     Document Type: Review

References (88)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 2 69 90 Epub 2011 Feb 4 10.3322/caac.20107 21296855
2. Multidisciplinary Management of Genitourinary Malignancies in Malcolm R. Alison, editor. Rathkopf D, Scher HI, The cancer handbook London: Jon Wiley & Son 2 2007 1432 52
3. Intravesical chemotherapy and bladder cancer. Wallerand H, Prog Urol 2009 19 12 868 71 10.1016/j.purol.2009.09.016 19963182
4. Treatment of uncommon malignant tumours of the bladder. Boyle H, Fléchon A, Droz JP, Curr Opin Urol 2011 21 5 309 14 10.1097/MOU. 0b013e3283495758 21814051
5. Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Ismaili N, Arifi S, Flechon A, El Mesbahi O, Blay JY, Droz JP, et al. Bull Cancer 2009 96 6 30 44 19457759
6. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE, J Clin Oncol 2010 28 11 1850 5 Epub 2010 Mar 15 10.1200/JCO.2009.25.4599 20231682
7. Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group study. Gagliano R, Levin H, El-Bolkainy MN, Wilson HE, Stephens RL, Fletcher WS, et al. Am J Clin Oncol 1983 6 2 215 8 10.1097/00000421-198304000-00014 6681934 (Pubitemid 13102162)
8. A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study. Soloway MS, Einstein A, Corder MP, Bonney W, Prout GR Jr, Coombs J, Cancer 1983 52 5 767 72 10.1002/1097-0142(19830901)52:5<767: :AID-CNCR2820520502>3.0.CO;2-P 6347356 (Pubitemid 13037634)
9. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. Harke WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, et al. J Clinl Oncol 1985 1463 70 (Pubitemid 16246757)
10. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. Troner M, Birch R, Omura GA, Williams S, J Urol 1987 137 4 660 2 3550148 (Pubitemid 17058673)
11. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, et al. J Urol 1985 133 3 403 7 4038749 (Pubitemid 15129797)
12. A critical review of the management of bladder cancer. Sternberg CN, Crit Rev Oncol Hematol 1999 31 3 193 207 10.1016/S1040-8428(99)00031-1 10532195 (Pubitemid 29424142)
13. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, et al. J Clin Oncol 1990 8 6 1050 5 2189954 (Pubitemid 20200193)
14. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. J Clin Oncol 1992 10 7 1066 73 1607913
15. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin,and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, et al. J Clin Oncol 2001 19 2638 46 11352955 (Pubitemid 32441368)
16. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Eur J Cancer 2006 42 50 4 10.1016/j.ejca.2005.08.032 16330205 (Pubitemid 41814532)
17. Spanish Oncology Genitourinary Group (SOGUG). Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Bellmunt J, Albiol S, de Olano AR, Pujadas J, Maroto P, Ann Oncol 2006 17 113 7 10.1093/annonc/mdj964 (Pubitemid 43985219)
18. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF, J Clin Oncol 2000 18 17 3068 77 11001674
19. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. J Clin Oncol 2005 4602 08 (Pubitemid 46224062)
20. Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece. Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer. Bamias A, Karadimou A, Lampaki S, Aravantinos G, Xanthakis I, Papandreou C, et al. J Clin Oncol 2011 29 suppl; abstr 4510
21. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. Burch PA, Richardson RL, Cha SS, Sargent DJ, Pitot HC, Kaur JS, et al. J Urol 2000 164 5 1538 42 10.1016/S0022-5347(05)67023-1 11025699
22. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G, J Clin Oncol 2000 18 1058 61 10694557 (Pubitemid 30123783)
23. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Dimopoulos MA, Bakoyannis C, Georgoulias V, Papadimitriou C, Moulopoulos LA, Deliveliotis C, et al. Ann Oncol 1999 10 1385 8 10.1023/A:1008379500436 10631471
24. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Garcia del Muro X, Marcuello E, Gumá J, Paz-Ares L, Climent MA, Carles J, et al. Br J Cancer 2002 86 326 30 10.1038/sj.bjc.6600121 11875692 (Pubitemid 34185111)
25. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. Sengelov L, Kamby C, Lund B, Engelholm SA, J Clin Oncol 1998 16 3392 7 9779718 (Pubitemid 28481638)
26. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized phase III study from the Hellenic Cooperative OncologyGroup. Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, et al. J Clin Oncol 2004 22 220 8 14665607 (Pubitemid 41095085)
27. Carboplatin-based chemotherapy for bladder cancer. Waxman J, Barton C, Cancer Treat Rev 1993 19 Suppl. C 21 5 8481930 (Pubitemid 23333414)
28. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. Redman BG, Smith DC, Flaherty L, Du W, Hussain M, J Clin Oncol 1998 16 1844 8 9586899
29. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, et al. J Clin Oncol 2000 18 2537 44 10893284 (Pubitemid 30432519)
30. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. Vaughn DJ, Malkowicz SB, Zoltick B, Mick R, Ramchandani P, Holroyde C, et al. J Clin Oncol 1998 16 255 60 9440750 (Pubitemid 28041606)
31. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G, Cancer 2004 100 8 1639 45 10.1002/cncr.20123 15073851 (Pubitemid 38456340)
32. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Bellmunt J, de Wit R, Albanell J, Baselga J, Eur J Cancer 2001 37 2212 5 10.1016/S0959-8049(01)00295-7 11677109 (Pubitemid 33001291)
33. Gemcitabine and carboplatinin advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Nogué-Aliguer M, Carles J, Arrivi A, Juan O, Alonso L, Font A, et al. Cancer 2003 97 2180 6 10.1002/cncr.10990 12712469 (Pubitemid 36444058)
34. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Shannon C, Crombie C, Brooks A, Lau H, Drummond M, Gurney H, Ann Oncol 2001 12 947 52 10.1023/A:1011186104428 11521800 (Pubitemid 32725767)
35. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Dogliotti L, Carten G, Siena S, Bertetto O, Martoni A, Bono A, et al. Eur Urol 2007 52 1 134 41 10.1016/j.eururo.2006.12.029 17207911 (Pubitemid 46803003)
36. A Phase II study of oxaliplatin in urothelial cancer. Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K, Stadler WM, Urol Oncol 2005 23 3 150 4 10.1016/j.urolonc.2004.11.008 15907713 (Pubitemid 40720378)
37. Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy MG, Daugaard G, et al. J Clin Oncol 2010 28:18s: abstract LBA4519
38. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, et al. Urol Oncol 2004 22 5 393 7 10.1016/j.urolonc.2004.01.002 15464919
39. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, et al. J Clin Oncol 2005 23 1185 91 10.1200/JCO.2005.05.089 15718315 (Pubitemid 46202275)
40. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. Meluch AA, Greco FA, Burris HA, O'Rourke T, Ortega G, Steis RG, et al. J Clin Oncol 2001 19 3018 24 11408496 (Pubitemid 32565438)
41. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, et al. Urol Oncol 2004 22 393 7 10.1016/j.urolonc.2004.01.002 15464919
42. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Ardavanis A, Tryfonopoulos D, Alexopoulos A, Kandylis C, Lainakis G, Rigatos G, Br J Cancer 2005 92 645 50 10.1038/sj.bjc.6602378 15685232 (Pubitemid 40460598)
43. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. Dumez H, Martens M, Selleslach J, Guetens G, De Boeck G, Aerts R, et al. Anticancer Drugs 2007 18 211 8 10.1097/CAD.0b013e328010ee5c 17159607 (Pubitemid 44967431)
44. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Gitlitz BJ, Baker C, Chapman Y, Allen HJ, Bosserman LD, Patel R, et al. Cancer 2003 98 1863 9 10.1002/cncr.11726 14584068 (Pubitemid 37310229)
45. Phase II trial of pemetrexed disodium and gemcitabine in advanced carcinoma of the urothelium (E4802): A trial of the Eastern Cooperative Oncology Group. Li S, Dreicer R, Roth B, Manoloa J, Cooney M, Wilding G, J Clin Oncol 2007 25 abstract 5079
46. A phase II trial of pemetrexed plus Gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. von der Maase H, Lehmann J, Gravis G, Joensuu H, Geertsen PF, Gough J, et al. Ann Oncol 2006 17 1533 8 10.1093/annonc/mdl154 16873433 (Pubitemid 44542040)
47. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, et al. J Clin Oncol 2000 18 18 3247 55 10986057
48. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. Bellmunt J, von der Maase H, Mead GM, Heyer J, Houede N, Paz-Ares LG, et al. J Clin Oncol 2007 25 abstract LBA5030
49. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, et al. Cancer 2000 88 1671 8 10.1002/(SICI)1097- 0142(20000401)88:7<1671::AID-CNCR22>3.0.CO;2-A 10738226 (Pubitemid 30183153)
50. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC, J Clin Oncol 2001 19 2527 33 11331332 (Pubitemid 32391224)
51. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Hainsworth JD, Meluch AA, Litchy S, Schnell FM, Bearden JD, Yost K, et al. Cancer 2005 103 11 2298 303 10.1002/cncr.21078 15856431 (Pubitemid 40686574)
52. Phase I/II study of paclitaxel, carboplatin ant methotrexate in advanced transitional cell carcinoma: a well tolerated regimen with activity independent of p53 mutation. Edelman MJ, Meyers FJ, Miller TR, William SG, Gandour Edwards R, De Vere white R, Urology 2000 55 521 5 10.1016/S0090-4295(99)00538-5 10736495 (Pubitemid 30157956)
53. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. Tu SM, Hossan E, Amato R, Kilbourn R, Logothesis, J Urol 1995 154 1719 22 10.1016/S0022-5347(01)66765-X 7563331
54. Platinum (PLAT) Free Combination Chemotherapy in Locally Advanced and Metastatic Transitional Cell Carcinoma (TCC): Phase I/II Trial of Gemcitabine (GEM), Paclitaxel (TAX), Methotrexate (MTX). Law LY, Lara PN, Meyers FJ, Dawson NA, Edelman MJ, J Clin Oncol 2001 20 abstract 767
55. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Pectasides D, Visvikis A, Aspropotamitis A, Halikia A, Karvounis N, Dimitriadis M, et al. Eu J Cancer 2000 36 74 9 (Pubitemid 30035347)
56. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, Iasonos A, Riches J, Regazzi A, Bajorin DF, J Clin Oncol 2009 27 25 4062 7 Epub 2009 Jul 27 10.1200/JCO.2008.21.2241 19636012
57. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Galsky MD, Iasonos A, Mironov S, Scattergood J, Boyle MG, Bajorin DF, Cancer 2007 109 3 549 55 10.1002/cncr.22454 17200962 (Pubitemid 46190963)
58. FOLFOX-4 in pretreated patients with advanced transitional cell carcinoma of the bladder. Di Lorenzo G, Autorino R, Giordano A, Giuliano M, D'Armiento M, Bianco AR, et al. Jpn J Clin Oncol 2004 34 747 50 10.1093/jjco/hyh132 15640506 (Pubitemid 41615272)
59. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Khorsand M, Lange J, Feun L, Clendeninn NJ, Collier M, Wilding G, Invest New Drugs 1997 15 157 63 10.1023/A:1005860806635 9220296 (Pubitemid 27248257)
60. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, et al. J Clin Oncol 2006 24 3451 7 10.1200/JCO.2005.03.6699 16849761 (Pubitemid 46638903)
61. Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report. Seo YR, Kim SH, Kim HJ, Kim CK, Park SK, Koh ES, Hong DS, J Hematol Oncol 2010 3 4 10.1186/1756-8722-3-4 20089186
62. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. J Clin Oncol 2009 27 27 4454 61 10.1200/JCO.2008.20.5534 19687335
63. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Albers P, Park SI, Niegisch G, Fechner G, Steiner U, Lehmann J, Heimbach D, Heidenreich A, Fimmers R, Siener R, AUO Bladder Cancer Group, Ann Oncol 2011 22 2 288 94 Epub 2010 Aug 2 10.1093/annonc/mdq398 20682548
64. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC) - Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial. Quinn DI, Aparicio A, Tsao-Wei DD, Groshen SG, Dorff TB, Synold TW, et al. J Clin Oncol 2010 28 abstract 4539
65. http://www.clinicaltrials.gov/ct2/results?term= %22bladder+cancer%22+metastatic+disease
66. Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). Hahn NM, Stadler WM, Zon RT, Waterhouse DM, Picus j, Nattam SR, et al. J Clin Oncol 2010 28 abstract 4541
67. Phase II study of sunitinib in patients with metastatic urothelial cancer. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, et al. J Clin Oncol 2010 28 8 1373 9 10.1200/JCO.2009.25.3922 20142593
68. A phase II study of sunitinib on a continuous dosing schedule in patients (pts) with relapsed or refractory urothelial carcinoma (UC). 2009 ASCO Annual Meeting. Gallagher DJ, Milowsky MI, Gerst SR, Tickoo S, Ishill N, Regazzi A, et al. J Clin Oncol 2009 27 abstract 5072
69. Maintenance sunitinib postchemotherapy (CT) in patients (pts) with advanced urothelial carcinoma (UC): a randomized placebo controlled phase II trial. Bradley D, Daignault S, Smith DC, Nanus D, Tagawa S, Stadler WM, et al. J Clin Oncol 2009 27 abstract 5073
70. Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC). Galsky MD, Sonpavde G, Hellerstedt BA, McKenney SA, Hutson TE, Rauch MA, et al. J Clin Oncol 2010 28 abstract 4573
71. First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit. Bellmunt J, Gonzalez-Larriba JL, Maroto JP, Carles J, Castellano DE, Mellado B, et al. J Clin Oncol 2010 28 abstract 4540
72. Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): a trial of the Eastern Cooperative Oncology Group. Dreicer R, Li H, Stein MN, DiPaola RP, Eleff M, Roth BJ, et al. J Clin Oncol 2008 26 abstract 5083
73. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). Krege S, Rexer H, vom Dorp F, Albers P, De Geeter P, Klotz T, J Clin Oncol 2010 28 abstract 4574
74. Open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3. Milowsky MI, Carlson GL, Shi MM, Urbanowitz G, Zhang Y, Sternberg CN, J Clin Oncol 2011 29 suppl; abstr TPS186
75. Prognostic value of amplification of c-erbB-2 in bladder carcinoma. Lönn U, Lönn S, Friberg S, Nilsson B, Silfverswärd C, Stenkvist B, Clin Cancer Res 1995 1 1189 94 9815911
76. Invasion of the bladder by transitional cell-carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erbB-2, epidermal growth factor receptor, and bcl-2. Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML, Cancer 1998 82 715 23 10.1002/(SICI)1097-0142(19980215)82:4<715::AID- CNCR15>3.0.CO;2-0 9477105 (Pubitemid 28090284)
77. HER2/neu overexpression in muscleinvasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA, et al. Clin Cancer Res 2001 7 2440 7 11489824 (Pubitemid 32751647)
78. Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/neu (c-erbB-2) status in urothelial carcinoma. De Pinieux G, Colin D, Vincent-Salomon A, Couturier J, Amsellem-Ouazana D, Beuzeboc P, et al. Virchows Arch 2004 444 415 9 10.1007/s00428-004-0986-4 15029496 (Pubitemid 38703757)
79. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermalgrowth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, et al. J Clin Oncol 2007 25 2218 24 10.1200/JCO.2006.08.0994 17538166 (Pubitemid 46954646)
80. Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: a Southwest Oncology Group Trial. Petrylak D, Faulkner JR, Van Veldhuizen PJ, Mansukhani M, Crawford ED, J Clin Oncol 2003 22 abstract 1619
81. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ, Cancer and Leukemia Group B, Ann Oncol 2009 20 6 1074 9 10.1093/annonc/mdn749 19168670
82. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al. Cancer 2009 115 13 2881 90 10.1002/cncr.24337 19399906
83. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Yuan R, Kay A, Berg WJ, Lebwohl D, J Hematol Oncol 2009 2 45 10.1186/1756-8722-2-45 19860903
84. H. Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. Milowsky MI, Trout A, Regazzi AM, Garcia-Grossman I, Flaherty A, Tickoo S, et al. J Clin Oncol 2010 28 abstract TPS229
85. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Tan J, Cang S, Ma Y, Petrillo RL, Liu D, J Hematol Oncol 2010 3 5 10.1186/1756-8722-3-5 20132536
86. Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. Xu XS, Wang L, Abrams J, Wang G, J Hematol Oncol 2011 4 17 10.1186/1756-8722-4-17 21507255
87. The role of chemotherapy in the management of bladder cancer. Ismaili N, Amzerin M, Elmajjaoui S, Droz JP, Flechon A, Errihani H, Prog Urol 2011 21 6 369 82 21620296
88. Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer? Ismaili N, Elmajjaoui S, Bensouda Y, Belbaraka R, Abahssain H, Allam W, et al. Oncol Rev 2011